Clinical Trials Using Sacituzumab Govitecan
Clinical trials are research studies that involve people. The clinical trials on this list are studying Sacituzumab Govitecan. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer
This is an international, multi-center, open-label, phase II study in patients with metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1 / PD-L1 based immunotherapy. At least 140 patients are anticipated to be enrolled across approximately 70 sites from North America, Europe and Asia.
Location: 11 locations
ASCENT-Study of Sacituzumab Govitecan in Refractory / Relapsed Triple-Negative Breast Cancer
This is an international, multi-center, open-label, randomized, Phase III study in patients with metastatic TNBC refractory or relapsing after at least 2 prior chemotherapies (including a taxane) for their metastatic disease. Patients meeting eligibility will be randomized 1:1 to receive either sacituzumab govitecan or treatment of physician choice (TPC) Patients will be treated until progression, unacceptable toxicity, study withdrawal, or death, whichever comes first. Tumor progression leading to treatment withdrawal will be assessed by the investigator. Starting with the initial dose of sacituzumab govitecan or TPC, Imaging assessments will be obtained at least every 8 weeks until the occurrence of progression of disease requiring discontinuation of further treatment. All patients, will be followed every 4 weeks during the first year and every 8 weeks thereafter for survival follow-up.
Location: 8 locations
Sacituzumab Govitecan in Treating Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Second Generation Androgen Receptor-Directed Therapy
This phase II trial studies how well sacituzumab govitecan works in treating patients with castration-resistant prostate cancer that has spread to other places in the body and progressed on second generation androgen receptor-directed therapy. Immunotherapy with sacituzumab govitecan may induce changes in the body’s immune system and may interfere with the ability of tumor cells to grow and spread.
Location: 3 locations
Sacituzumab Govitecan in Treating Patients with Breast Cancer Brain Metastasis or Recurrent Glioblastoma
This early phase I trial studies the extent by which sacituzumab govitecan is able get into the brain in treating patients with breast cancer that has spread to the brain (brain metastasis) or glioblastoma that has come back after previous treatment (recurrent). Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug called govitecan. Sacituzumab attaches to TROP2 positive tumor cells in a targeted way and delivers govitecan to kill them.
Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR)
This is an open label, Phase 1b / 2 study with multiple treatment arms evaluating the safety, tolerability, PK, and preliminary efficacy of rucaparib in combination with a second anticancer therapy in patients with an advanced / metastatic solid malignancy (Phase 1b), followed by evaluation of the combination in one or more specific patient populations in an expansion phase (Phase 2 cohorts).
Location: M D Anderson Cancer Center, Houston, Texas
Study of IMMU-132 in HR+ / HER2- MBC (TROPICS-02)
This is an open-label, randomized, multicenter Phase 3 study to compare the efficacy and safety of Sacituzumab Govitecan versus TPC in subjects with metastatic or locally recurrent inoperable HR+ / HER2- MBC, after failure of at least 2, and no more than 4, prior chemotherapy regimens for metastatic disease.
Location: 5 locations
A Study of Sacituzumab Govitecan in Metastatic Solid Tumors (Tropics-03)
A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU0132) in Subjects With Metastatic Solid Tumors
Location: 2 locations